MIR613

Summary

MIR613 (microRNA 613, HGNC:32869) is a microRNA gene on chromosome 12p13.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 693198 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32869
Approved symbol	MIR613
Name	microRNA 613
Location	12p13.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-613
Ensembl gene	ENSG00000207983
Ensembl biotype	miRNA
Entrez	693198
RNAcentral	URS000075EF41 — miRNA, 95 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385248

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385248 — 1 exons

Exon	Start	End
ENSE00001500254	12764649	12764743

Expression profiles

Bgee: expression breadth broad, 59 present calls, max score 82.25.

Top tissues by expression

59 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	82.25	gold quality
stomach	UBERON:0000945	82.08	gold quality
blood	UBERON:0000178	81.49	gold quality
corpus callosum	UBERON:0002336	78.69	gold quality
heart	UBERON:0000948	77.59	gold quality
fundus of stomach	UBERON:0001160	76.96	gold quality
gastrocnemius	UBERON:0001388	76.29	gold quality
adrenal tissue	UBERON:0018303	75.65	gold quality
kidney	UBERON:0002113	72.76	gold quality
intestine	UBERON:0000160	72.36	gold quality
lung	UBERON:0002048	71.89	gold quality
heart left ventricle	UBERON:0002084	71.58	gold quality
calcaneal tendon	UBERON:0003701	71.32	gold quality
myometrium	UBERON:0001296	70.64	gold quality
right atrium auricular region	UBERON:0006631	70.61	gold quality
left coronary artery	UBERON:0001626	70.50	gold quality
endometrium	UBERON:0001295	70.25	gold quality
tibial artery	UBERON:0007610	70.07	gold quality
hypothalamus	UBERON:0001898	69.23	gold quality
right hemisphere of cerebellum	UBERON:0014890	68.68	gold quality
lower esophagus muscularis layer	UBERON:0035833	68.66	gold quality
muscle layer of sigmoid colon	UBERON:0035805	67.82	gold quality
body of stomach	UBERON:0001161	67.81	gold quality
small intestine Peyer’s patch	UBERON:0003454	67.61	gold quality
esophagus mucosa	UBERON:0002469	67.05	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	66.52	gold quality
skin of leg	UBERON:0001511	66.46	gold quality
colon	UBERON:0001155	66.43	gold quality
zone of skin	UBERON:0000014	66.23	gold quality
skin of abdomen	UBERON:0001416	65.93	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.17

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1H3, SREBF1

Literature-anchored findings (GeneRIF, showing 40)

• hsa-miR-613 targeted and down-regulated the expression of human nuclear receptor liver X receptor-alpha (PMID:21310851)
• MiR-613 suppresses lipogenesis by directly targeting LXRalpha in HepG2 cells. (PMID:23496987)
• PPARgamma negatively regulates the expression of miR-613 at transcriptional level, and miR-613 suppressed LXRalpha and ABCA1 by targeting the 3’-UTR of their mRNAs. (PMID:24751522)
• In conclusion, miR-613 is significantly reduced in cancerous tissue and serum samples of esophageal squamous cell cancer (ESCC)patients. It can serve as an ideal indicator for the diagnosis and prognosis of ESCC. (PMID:26499784)
• miR-613 is frequently downregulated in ovarian cancer and is a potential tumor-suppressing miRNA that may decrease ovarian cancer development and/or progression. KRAS regulation by miR-613 might play a role in its regulation of the malignant behavior of ovarian cancer. (PMID:26631045)
• conclusion, our study suggests that miR-613 functions as a tumor suppressor, partially through targeting Fzd7, and is a potential therapeutic target for prostate cancer. (PMID:26703210)
• both miR-613 mimics and inhibitors could decrease and increase CDK4 protein levels in non-small cell lung cancer-derived cells, respectively. (PMID:26744345)
• Expression levels of miR-613 are low in ovarian cancer tissue and correlate with progression-free and overall survival. (PMID:27010138)
• first evidence for the suppressive activity of miR-613 in hepatocellular carcinoma, which is causally linked to targeting of DCLK1 (PMID:27049311)
• miR-613 functions as a tumor suppressor in papillary thyroid carcinoma and its suppressive effect is mediated by repressing SphK2 expression (PMID:27223438)
• miR-613 inhibits ischemia-reperfusion-induced cardiomyocyte apoptosis by targeting PDCD10 and regulating the PI3K/AKT signaling pathway. (PMID:27534371)
• Our data collectively indicate that miR-613 functions as a tumor suppressor in retinoblastoma through downregulating E2F5, supporting the targeting of the novel miR-613/E2F5 axis as a potentially effective therapeutic approach for retinoblastoma. (PMID:28351331)
• Study shows the expression of miR-613 down-regulated in pancreatic cancer tissues and cell lines. Its down-regulation was positively correlated with tumor differentiation, advanced TNM stage, nodal metastasis and shorter overall survival in patients with pancreatic cancer. Its overexpression suppressed cell proliferation, invasion and migration, and induced cell apoptosis and cell cycle arrest at G0/G1. (PMID:28415631)
• miR-613, as a tumour suppressor, involves in gastric cancer progression and metastasis by targeting CDK9 (PMID:28701053)
• our data provide compelling evidence that human cytomegalovirus reduced the level of microRNA-613 which functions as an anti-onco-miRNA in glioblastoma, primarily by downregulating the expression of arginase-2 (PMID:28718378)
• MiR613 suppressed the protein and mRNA expression levels of VEGFA and Ectopic expression of miR613 markedly suppressed glioma cell proliferation and angiogenesis. (PMID:28901424)
• The miR613 overexpression remarkably suppressed FZD7 protein expression and restoration of FZD7 significantly reversed the suppressive effects of miR613 on RCC cell proliferation and invasion. (PMID:29067457)
• miR-613 is involved in cell migration and invasion of triple-negative breast cancer cells via targeting Daam1/RhoA signaling pathway. (PMID:29339084)
• Study demonstrated that expression of miR-613 was signi fi cantly lower in hepatocellular carcinoma (HCC) tissues compared with adjacent normal tissues. Overexpression of miR-613 inhibited cell proliferation and invasion by targeting YWHAZ in HCC cells. (PMID:29551505)
• that miR-34c and miR-613 could reverse the oncogenic function of differentiation antagonizing non-protein coding RNA in retinoblastoma tumorigenesis (PMID:29744877)
• This effect can be suppressed by miR-613 through directly downregulating CXCR4. (PMID:29845707)
• MiR-613 promotes cell proliferation and invasion in cervical cancer via targeting PTPN9 (PMID:30024598)
• the role of lncRNA HOTAIR/miR-613/c-met signalling axis in modulating retinoblastoma cells’ viability, apoptosis and expressions of EMT-specific proteins might provide evidences for developing appropriate diagnostic and treatment strategies for retinoblastoma. (PMID:30030888)
• MiR-613 is an oncogene in colon cancer and promotes the proliferation, invasion and migration of colon cancer cells by targeting ATOH1 likely via activating JNK1 pathway and up-regulating MUC2. (PMID:30219232)
• These findings suggested that LINC00460 could function as a competing endogenous RNA to regulate SphK2 expression by sponging miR-613 in papillary thyroid carcinoma. (PMID:30478856)
• MiR-613 can inhibit proliferation and invasion and induce apoptosis of rheumatoid arthritis synovial fibroblasts by directly targeting DKK1 expression. (PMID:31019537)
• Data observed miR-613 expression was downregulated in both chemoresistant and recurrent hepatocellular carcinoma (HCC) patients. Down-regulation of miR-613 facilitated liver cancer stem cells (CSCs) expansion by promoting the dedifferentiation of hepatoma cells and enhancing the self-renewal of liver CSCs. (PMID:31075412)
• miR-613 served as a tumor suppressor by targeting PFKFB2, indicating that detecting miR-613 and modulation of miR-613 expression could be potential marker and clinical approach in gastric cancer patients (PMID:31122697)
• LncRNA SNHG14 potentiates pancreatic cancer progression via modulation of annexin A2 expression by acting as a competing endogenous RNA for miR-613. (PMID:31513352)
• Long noncoding RNA cytoskeleton regulator RNA promotes cell invasion and metastasis by titrating miR-613 to regulate ANXA2 in nasopharyngeal carcinoma. (PMID:31859457)
• Data suggest that circCCT3 circular RNA plays an oncogenic role in colorectal cancer (CRC) metastasis through miR-613/vascular endothelial growth factor A (VEGFA) and Wnt signaling. (PMID:31859543)
• MicroRNA-613: A novel tumor suppressor in human cancers. (PMID:31877552)
• MiR-613 blocked the progression of cervical cancer by targeting LETM1. (PMID:32633345)
• Long non-coding RNA LINC00152/miR-613/CD164 axis regulates cell proliferation, apoptosis, migration and invasion in glioma via PI3K/AKT pathway. (PMID:32726126)
• Knockdown of Long Noncoding RNA Urothelial Carcinoma-Associated 1 Represses Gallbladder Cancer Advancement by Regulating SPOCK1 Expression Through Sponging miR-613. (PMID:33090888)
• The Long Intergenic Noncoding RNA 00707 Sponges MicroRNA-613 (miR-613) to Promote Proliferation and Invasion of Gliomas. (PMID:33107401)
• Long Noncoding RNA HOTAIR Functions as a Competitive Endogenous RNA to Regulate Connexin43 Remodeling in Atrial Fibrillation by Sponging MicroRNA-613. (PMID:33294032)
• miR-613 inhibits the proliferation of human ovarian granulosa cells by arresting cell cycle progression via the targeting of IGF-1. (PMID:33398375)
• LncRNA PSMG3AS1 promotes proliferation of non-small cell lung cancer cells by sponging miR-613 to upregulate SphK1. (PMID:33849377)
• MiR-613 Promotes Cell Death in Breast Cancer Cells by Downregulation of Nicotinamide Phosphoribosyltransferase and Reduction of NAD. (PMID:34101492)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.